Best Available Copy

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions of the claims and listing of the claims in the application:

1. (Currently Amended) A compound having formula (I):



I

or a pharmaceutically acceptable salt thereof, wherein X is



R^1 is halogen, lower alkyl ~~or lower cycloalkyl~~;

R^2 is attached to any available carbon atom of the phenyl ring A and at each occurrence is ~~independently selected from the group consisting of~~ alkyl, ~~lower cycloalkyl, halo, trifluoromethyl, trifluoromethoxy, -OMe, -CN and -NMe_2~~;

n is 0 or 1;

Y is –L-R^3;

R^3 is hydrogen, alkyl, ~~-OR^4~~, substituted alkyl, cycloalkyl, ~~-CR^4cycloalkyl, a saturated 4 to 7 membered mono cyclic heterocyclyl or a substituted saturated 4 to 7 membered mono cyclic heterocyclyl~~;

L is –C(=O)NH-, -NH(C=O)-;

V is –M-R^{10} ~~or R^{14}~~;

M is –C(=O)NR^4-, -NR^4(C=O)-, -NR^4(C=O)NR^4-, -NR^4SO_2-, or -C(=O)-;

~~R^{14} is aryl or heteroaryl optionally substituted with up to three R^{12}~~;

R^4 is each selected from hydrogen, lower alkyl and lower cycloalkyl;

Best Available Copy

R^6 ~~is attached to any available carbon atom of the phenyl ring B and~~ at each occurrence is independently hydrogen, alkyl, ~~lower cycloalkyl, halo, trifluoromethyl, trifluoromethoxy, -OMe, -CN,~~ $-NH_2$, or $-NMe_2$;

R^{10} is alkyl, substituted alkyl, aryl, or $-(CH_2)_t-D-(CH_2)_e-R^{13}$;

t is selected from 0, 1, 2 and 3; e is selected from 0, 1, 2 and 3;

D is selected from a bond, an optionally substituted heterocyclyl, an optionally substituted aryl, -O-, -S-, -(C=O)-, $-NR^4(C=O)-$, $-(C=O)NR^4-$, -S(O)-, SO_2NR^4-, SO_2-, and $-NR^4-$;

~~R^{12} is selected from R^{40}, NO_2, CN, lower cycloalkyl, halo, trifluoromethyl, trifluoromethoxy, -OMe, -CN, $-NMe_2$, -S(=O)alkyl, -S(=O)aryl, $-NHSO_2$-aryl-R^4, $-NHSO_2$alkyl, $-CO_2R^4$, $-CONH_2$, $-SO_3H$, -S(O)alkyl, -S(O)aryl, $-SO_2NHR^4$, and $-NHC(=O)NHR^4$; and~~

R^{13} is selected from an optionally substituted five- to seven-membered heterocyclic ring, an optionally substituted five- to seven-membered heteroaryl ring and an optionally substituted fused bicyclic ring.

2. (Cancelled)

3. (Previously Presented) The compound of claim 1 having formula (III):



III.

4. (Cancelled)

5. (Previously Presented) The compound of claim 1 having formula (V):



V.

6-11. (Cancelled)

12. (Previously Presented) The compound of claim 1, wherein R^6 is lower alkyl or hydrogen.

13-19. (Cancelled)

Best Available Copy

20. (Previously Presented) The compound of claim 1, wherein M is –C(=O)NR^4-.

21. (Previously Presented) The compound of claim 1, wherein M is –C(=O)NH–.

22. (Cancelled)

23. (Currently Amended) The compound of claim 1, wherein R^{10} is 4-methoxybenzyl.

24-28.(Cancelled)

29. (Previously Presented) The compound of claim 1, wherein R^1 is lower alkyl.

30-33. (Cancelled)

34. (Previsouly Presentedd) The compound of claim 1, wherein R^3 is lower alkyl or lower cycloalkyl.

35. (Previously Presented) The compound of claim 1, wherein R^3 is lower cycloalkyl.

36. (Previously Presented) The compound of claim 1, wherein R^3 is cyclopropyl.

37. (Previously Presented) The compound of claim 1: *N*-(4-Methoxybenzyl)-2-[(5-cyclopropylaminocarbonyl)-2-methylphenyl]-4-aminopyrimidine-5-carboxyamide.

38-53. (Cancelled)

54. (Previously Presented) A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

55-61. (Cancelled)